Approved prescription medicine - dual agonist
Tirzepatide
Approved dual GIP/GLP-1 agonist - and why research listings are not it
Tirzepatide is a dual agonist acting on both GIP and GLP-1 receptors, developed by Eli Lilly and approved as a prescription medicine for type 2 diabetes and for chronic weight management. Unlike most compounds on this site, it has a completed clinical programme, a regulator-reviewed safety profile, and an approved manufacturing supply chain.
That creates a distinction worth being precise about. The approved medicine and material sold as 'tirzepatide' for research are not the same product, even though the molecule is the same. One has been assessed by a regulator; the other has not, and the certificate of analysis is the only thing standing between you and an unknown vial.
Regulatory status
Tirzepatide is FDA-approved and available by prescription. Compounding of tirzepatide was permitted only while the FDA listed it in shortage; once the shortage resolved, that route closed, and the FDA has taken action against compounded versions marketed as equivalent. Research-chemical listings are not the approved medicine and are not legal substitutes for a prescription.
Mechanism
GIP agonism
The addition that distinguishes tirzepatide from GLP-1-only medicines. GIP receptors are found on pancreatic cells and in adipose tissue, and the combined action is proposed to explain the larger average weight reductions seen in trials.
GLP-1 agonism
The shared mechanism across this drug class: reduced appetite, slowed gastric emptying, and glucose-dependent insulin release.
Approved formulation matters
The approved product is a specific formulation studied in specific presentations. Research material is a lyophilised powder, which is a different handling and stability situation entirely.
Research status
Tirzepatide has completed Phase 3 trials in type 2 diabetes (the SURPASS programme) and in obesity (SURMOUNT), and is approved for both indications. This is a genuinely well-characterised molecule. The important caveat is that this evidence describes the approved medicine, not research-grade material sold under the same name - the trial data does not transfer to an unverified vial.
Verifying a batch
- 01For a compound with an approved reference standard, identity testing is more meaningful than for an unapproved molecule - expect mass spectrometry against a real standard.
- 02Purity and peptide content are separate figures. Ask for both.
- 03Check the batch code matches the certificate, and that the issuing lab is named and independent.
- 04Lyophilised powder is not the approved formulation; storage and handling requirements differ from the medicine.
Search lab reports for this compound →How purity is tested →
Questions
Is tirzepatide approved?+
Yes. It is FDA-approved and prescribed for type 2 diabetes and chronic weight management, sold under brand names.
Is research-grade tirzepatide the same as the medicine?+
It contains the same molecule but is not the same product. Research material is not regulator-assessed and is not a legal substitute for a prescription.
Why did compounded tirzepatide stop?+
Compounding was permitted only during an FDA-declared shortage. When the shortage resolved, the justification for compounding ended.
How does it compare to semaglutide?+
Semaglutide acts on GLP-1 alone; tirzepatide adds GIP agonism. Head-to-head trials have reported larger average weight reductions with tirzepatide, though individual responses vary.
Related compounds
Looking for Tirzepatide?
Join our next group buy to get verified quality at wholesale prices.
All compounds listed here are supplied for laboratory research use only and are not medicines, supplements, or products for human consumption.